Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Non-Current Assets (2016 - 2025)

IGC Pharma (IGC) has disclosed Other Non-Current Assets for 15 consecutive years, with $680000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $680000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $680000.0, a N/A change, with the full-year FY2025 number at $681000.0, down 1.02% from a year prior.
  • Other Non-Current Assets was $680000.0 for Q2 2025 at IGC Pharma, roughly flat from $681000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.0 million in Q2 2023 to a low of $603000.0 in Q1 2021.
  • A 5-year average of $787000.0 and a median of $687500.0 in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 2412.5% in 2021, then crashed 31.41% in 2024.
  • IGC Pharma's Other Non-Current Assets stood at $603000.0 in 2021, then skyrocketed by 55.39% to $937000.0 in 2022, then increased by 8.54% to $1.0 million in 2023, then tumbled by 32.45% to $687000.0 in 2024, then dropped by 1.02% to $680000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Other Non-Current Assets are $680000.0 (Q2 2025), $681000.0 (Q1 2025), and $687000.0 (Q3 2024).